Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emi Ebihara"'
Autor:
Yudai Uehira, Hiroaki Ueno, Emi Ebihara, Taisuke Uchida, Hiroki Nabekura, Hideyuki Sakoda, Tadato Yonekawa, Hideki Yamaguchi, Masamitsu Nakazato
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 6, Pp 1011-1020 (2022)
ABSTRACT Aims/Introduction The Japanese diabetes treatment guidelines do not specify the first choice of hypoglycemic agents, unlike those of Western countries. Furthermore, the current situation in diabetes treatment is that the choice of hypoglycem
Externí odkaz:
https://doaj.org/article/f18b07338e4548c59d368093b468298d
Autor:
Hiroaki Ueno, Yui Yano, Naoki Haraguchi, Tomomi Shiiya, Emi Ebihara, Eri Sumoto, Miyo Nakamura, Keiko Sasaba, Taisuke Uchida, Masamitsu Nakazato, Tomoho Noda, Emiko Kita, Tomoko Nobe, Akemi Umemura, Mayumi Azuma, Yudai Uehira, Naho Uchimura
Publikováno v:
Journal of the American Nutrition Association.
OBJECTIVE Konjac is a food mainly consumed in Asian countries with high fiber and low energy. Although glucomannan, a component of konjac, have been used for several clinical studies, there is few reports using konjac itself. This study examined the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b3072f35d9841f845160f88df5a2ef
https://pubmed.ncbi.nlm.nih.gov/34843410
https://pubmed.ncbi.nlm.nih.gov/34843410
Autor:
Yuri Tanaka, Emi Ebihara, Yousuke Murakami, Masamitsu Nakazato, Tomoho Noda, Hideki Yamaguchi, Keisuke Sadohara, Wakaba Tsuchimochi, Hiroaki Ueno, Hideyuki Sakoda, Shinichi Yonamine, Yuuma Nagatomo
Publikováno v:
Diabetes Therapy
Introduction We investigated the mechanisms of the glucose-lowering effects of teneligliptin and canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, by monitoring several gastrointestinal peptides using the most appropriate measuring m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a99b48c11f1dd0f9b43b5b05d32c4e
https://doi.org/10.1007/s13300-019-0666-7
https://doi.org/10.1007/s13300-019-0666-7
Autor:
Emi Ebihara, Masamitsu Nakazato, Kenji Noma, Hiroko Nakazato, Takahisa Kawano, Kazuhiro Nagamine, Hideyuki Sakoda, Hiroaki Ueno
Publikováno v:
Diabetes Therapy
Introduction Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8966e27a7293685c155ba0cff289638e
http://europepmc.org/articles/PMC5801252
http://europepmc.org/articles/PMC5801252